MedTrace Logo

A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)

NCT00701545 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2011-02-11

No results posted yet for this study

Summary

As part of CSL Behring Canada's continued commitment to ensuring the safety of the new low volume preparation of Humate-P®, CSL Behring Canada proposes to conduct a prospective, multi-center structured data collection of routine management of patients with von Willebrand disease treated with Humate P® ivr in Canada. The surveillance will be non-interventional and non-experimental. During the observation period, the routine medical care of the patient will be documented.

It is expected that there will be no difference in the safety and tolerability of Humate-P® ivr compared to Humate-P®

Conditions

  • Von Willebrand Disease

Sponsors & Collaborators

  • CSL Behring

    lead INDUSTRY

Principal Investigators

  • David G. Barnes, Dr. · CSL Behring Canada

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Completion
2009-04-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00701545 on ClinicalTrials.gov